Genomic structural variants comprise a significant fraction of somatic mutations driving cancer onset and progression. However, such variants are not comprehensively revealed by standard technologies, such as NGS (Next Generation Sequencing).

Many laboratories have leveraged optical genome mapping (OGM) as a tool to unlock a better understanding of these types of variants, across multiple tumor types.

During this session, we will dive into some examples of how OGM has unlocked breakthrough pathogenic findings, with important implications for understanding cancer etiology and potential impact on healthcare. We will start with an introduction to OGM and Bionano’s recent product launches to unlock a scalable sample to answer workflow.

We will then follow with Dr. Ying S. Zou, from Johns Hopkins, who will delve into the use of OGM in providing deeper insights into sarcomas.

Dr. Christine Lefebvre from CHU Grenoble rounds out the session by presenting her work on using OGM to advance the understanding of lymphomas.

Overall, the session highlights significant strides in the application of the OGM workflow within oncological research, showcasing its potential to uncover critical pathogenic variants in complex cancer types.

Webinar learning objectives:

Introduction and Applications of Optical Genome Mapping (OGM): An overview of OGM technology, including recent advancements and product launches by Bionano. The session will highlight how OGM offers a scalable workflow to comprehensively reveal structural variants that are missed by NGS, and its significant role in enhancing our understanding of cancer genetics.
Insights into Sarcomas through OGM: Dr. Ying S. Zou's presentation will focus on the specific application of optical genome mapping in the study of sarcomas. Attendees will learn about the groundbreaking discoveries enabled by OGM, providing deeper insights into the genetic complexities of sarcomas.
Advancements in Lymphoma Research Using OGM: Dr. Christine Lefebvre will discuss her work in applying OGM to advance the understanding of lymphomas. The session will explore how this technology has facilitated significant breakthroughs in identifying pathogenic variants within lymphomas.

Christine Lefebvre MD, PhD

Hematologist, Oncohematological Cytogenetic, Laboratoire de Génétique des hémopathies CHU Grenoble Alpes

Appearances